Date de publication: 23 octobre 2020
Promoteur – Intermédiaire Financier
ONCOPEPTIDES AB (PUBL)
Quasi equity financing to Oncopeptides - a publicly listed Swedish biotech developing targeted therapies for difficult-to-treat haematological diseases such as Relapsed and Refractory Multiple Myeloma.
The proposed transaction will support research and development (R&D) investments required to bring a melflufen programme to market, addressing a high unmet medical need, Multiple Myeloma (a rare form of cancer), in a growing patient population. In addition, it will support the company's development of its drug pipeline, preserving and cultivating highly skilled employment opportunities.
The company is publicly listed: any communication to be withheld until after signature of the finance contract and coordination with the company.
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 40 million
Coût total (montant approximatif)
EUR 166 million
The Promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending 2011/92/EU. Full environmental details verified during appraisal.
Passation des marchés
The Promoter is a public company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services verified details during the project due diligence.
Signé - 14/10/2020
Clause de non-responsabilité
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).